Journey Medical Corporation ((DERM)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Journey Medical’s latest earnings call painted a picture of a company gaining real traction, powered by Emrosi’s breakout performance and tighter financial discipline. Management emphasized strong revenue growth, a swing to positive adjusted EBITDA, and a healthier cash position, while acknowledging ongoing margin noise, uneven payer quality coverage, and a still‑negative GAAP bottom line.
Strong Top-Line Growth
Journey Medical reported Q1 2026 revenue of $16.0M, up 21% from $13.1M a year earlier, signaling durable growth beyond the initial launch phase. The company framed this performance as evidence that its commercial model is scaling, with Emrosi now a meaningful contributor rather than a small test brand.
Emrosi Revenue Acceleration
Emrosi was the star of the quarter, delivering net revenue of $6.3M compared with $2.1M in Q1 2025, roughly a 200% year‑over‑year jump. Sequentially, Emrosi revenue climbed about 26% from Q4, underscoring growing adoption and setting expectations that it will remain the primary growth engine.
Prescription Volume Momentum
Emrosi prescriptions reached roughly 30,000 in Q1, up from about 27,000 in Q4, an 11% sequential gain that highlights rising demand. The refill‑to‑new‑prescription ratio is approaching 1.5:1 from 1:1 at the end of 2025, suggesting improving patient persistence and satisfaction with the therapy.
Improving Profitability Metrics
Profitability trends turned notably better, with GAAP net loss narrowing to $2.2M, or $0.08 per share, from $4.1M, or $0.18, in the prior‑year quarter. Adjusted EBITDA flipped to a positive $0.6M from a negative $0.9M, an important milestone for investors tracking the path toward sustainable earnings.
Disciplined Expense Management
Operating expenses rose only about 6% year over year, markedly slower than revenue growth, highlighting emerging operating leverage. SG&A actually declined to $10.1M from $10.6M, showing that management is growing the top line without letting overhead balloon.
Stronger Balance Sheet Liquidity
The balance sheet improved, with cash increasing to $27.2M at quarter‑end from $24.1M at the end of 2025, a roughly 13% rise. Management pointed to this strengthened cash position as giving the company sufficient runway to keep investing in Emrosi promotion and targeted pipeline additions.
Commercial and Payer Progress
On the access front, Journey signed deals with the three largest PBM‑owned or affiliated GPOs, giving Emrosi potential reach to about 169M of 192M commercial lives. Unique dermatology prescribers rose to roughly 3,700 from about 3,200 at year‑end, a 15.6% increase that broadens the franchise’s base.
Clinical and Market Validation
Emrosi’s Phase III data were published in JAMA Dermatology, adding high‑quality clinical validation to the commercial story. Favorable citations in National Rosacea Society treatment algorithms and up to three additional planned publications in 2026 are expected to support further payer uptake and guideline inclusion.
Gross Margin Impact from One-Time Charge
Reported gross margin slipped to 61% from 63.5% in the year‑ago period, pressured by a $1.3M noncash API write‑down tied to the 2021 Qbrexza acquisition. Management stressed that excluding this one‑time item, gross margin would have been around 69%, implying underlying economics remain attractive.
Revenue-per-Script Volatility
Revenue per script has been choppy, dropping from about $271 in Q3 2025 to roughly $188 in Q4 before rebounding to around $202 in Q1. Executives attributed this volatility to normal ASP adjustments in the first 18–24 months after launch as payer contracts, discounts, and patient support programs settle.
Limited Quality Coverage Today
Despite broad GPO access, only about 34% of roughly 190M commercial lives currently enjoy single‑step or better Emrosi coverage, or around 60M lives. Management acknowledged that significant downstream formulary work remains to convert reach into high‑quality coverage that can fully unlock the brand’s potential.
Ongoing GAAP Loss
Journey remains loss‑making on a GAAP basis, with the Q1 net loss at $2.2M despite the improved trajectory. The company reiterated that further revenue scale and better reimbursement will be needed before it can consistently generate GAAP profits, a key watchpoint for investors.
Concentration Risk on Emrosi
The call underscored how central Emrosi has become, with the bulk of growth and narrative tied to this single asset. Management described other brands and up to two potential niche launches as incremental opportunities, but made clear that Emrosi is the core driver of value for now.
Legacy Brand and Inventory Actions
Legacy product Qbrexza was repositioned, including a move from P1 to P2 and an associated API inventory write‑down, reflecting a strategic reset of that franchise. These actions signal an effort to clean up inherited assets and refocus capital on higher‑return programs like Emrosi.
Guidance and Outlook
Formal quantitative guidance will come later this year, but management set a directional goal of maintaining positive adjusted EBITDA and positive EBITDA for the rest of 2026 and beyond. They plan modest sales force expansion and selective niche launches while working to stabilize margins, improve payer quality coverage, and extend Emrosi’s growth curve.
Journey Medical’s earnings call showcased a company turning clinical momentum into commercial and financial progress, led by Emrosi’s rapid ramp and improving profitability metrics. Investors will now watch closely to see if management can translate broad access into better payer quality coverage, smooth out ASP volatility, and ultimately cross the threshold into durable GAAP profitability.